Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model

Virology

Volumn 294, Issue 2, 2002, Pages 270-281

  Earl, Patricia L ^a   Wyatt, Linda S ^a   Montefiori, David C ^b   Bilska, Miroslawa ^b   Woodward, Ruth ^c   Markham, Phillip D ^c   Malley, James D ^a   Vogel, Thorsten U ^d   Allen, Todd M ^d   Watkins, David I ^d,e   Miller, Nancy ^a   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Oligomeric env protein; Recombinant modified vaccinia virus Ankara; Rhesus macaque; SHIV 89.6P; SHIV89.6; Vaccine

Indexed keywords

GAG PROTEIN; NEUTRALIZING ANTIBODY; POL PROTEIN; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BODY BURDEN; CONTROLLED STUDY; DRUG EFFECT; EUTHANASIA; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SOLUBILITY; T LYMPHOCYTE SUBPOPULATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIREMIA; VIRUS INFECTION; VIRUS LOAD; VIRUS RECOMBINANT;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS;

EID: 0036056987     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.1345     Document Type: Article

References (64)

1. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from SIV
2. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
3. Phenotypic analysis of antigen-specific T lymphocytes
4. Control of a mucosal challenge and prevention of AIDS in rhesus macaques by a multiprotein DNA/MVA vaccine
5. The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses
6. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
7. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination
8. Control of viremia and prevention of chinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
9. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 98.6 protein
10. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
11. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine
12. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
13. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization
14. An adenovirus simian immunodeficiency virus Env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
15. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector
16. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in nonhuman mammalian cell line
17. + T-cell-depleted rhesus macaques
18. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
19. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults
20. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response
21. Characterization of primary isolate-like variants of simian-human immunodeficiency virus
22. Effects of deletion or stringent repression of the H3L envelope gene on vaccinia virus replication
23. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus
24. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
25. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection
26. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults
27. HIV-1 vaccine-induced responses which correlate with protection from SHIV infection: Compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates
28. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
29. A simple sequentially rejective multiple test procedure
30. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys
31. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
32. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing
33. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: Effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses
34. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
35. Simian immunodeficiency virus DNA vaccine trial in macaques
36. Utility of SHIV for testing HIV-1 vaccine candidates in macaques
37. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA
38. The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defense mechanism
39. Abstammung, eigen-schaften und verwendung des attenuieten vaccinia-stammes MVA
40. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
41. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
42. Immunization against SIVmne in macaques using multigenic DNA vaccines
43. Comparative efficacy of recombinant modified vaccinia virus ankara expressing simian immunodeficiency virus (SIV) gag-Pol and/or env in macaques challenged with pathogenic SIV
44. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in macaques
45. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
46. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
47. Vaccine protection against a heterologous, non-synctium-inducing, primary human immunodeficiency virus
48. DNA vaccines for immunodeficiency viruses
49. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
50. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology
51. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
52. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
53. Modified sequentially rejective multiple test procedures
54. Anti-HIV env immunities elicited by nucleic acid vaccines
55. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques
56. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: Effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus
57. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins
58. Nonreplicating vaccinia vector efficiently expresses recombinant genes
59. A recombinant vector derived from the host-range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus
60. Protection of rhesus macaques from homologous and heterologous SHIV challenge using oligomeric gp140
61. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in rhesus macaques: Evidence for viral clearance
62. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but non-infectious virions
63. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal mode